Your Health, We Care
Another NameVonjo、LuciPac、帕克替尼
IndicationsIt is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary myelofibrosis and a platelet count of less than 50 × 10⁹/L.
Reg No.04 L 1337/25
Inspection NO.758-25
Pacritinib, an oral JAK2 inhibitor manufactured by Lucius Pharmaceuticals, provides a targeted treatment option for myelofibrosis patients with low platelet counts.
Summary of Key Information for Pacritinib.
Its main active ingredient is pacritinib.
It is indicated for adult patients with intermediate- or high-risk primary or secondary myelofibrosis and low platelet counts.
The recommended dose is 200 mg, administered orally twice daily, with or without food.
Dose adjustment is required for patients with severe hepatic impairment. Patients with renal impairment should avoid the use of this drug. Men and women of reproductive potential, as well as lactating women, need to be aware of the relevant risks.
Overdose may cause gastrointestinal reactions and myelosuppression, among other adverse effects. There is no specific antidote available.
Store in the original sealed packaging at room temperature below 30°C, protected from light.
This drug is mainly metabolized by CYP3A4, with a half-life of approximately 28 hours and a high average accumulation rate at steady state.
FDA，2025.10
